ShehlaWynne Ph.D.

Associate

Washington + 1.202.879.3718

Connect:

Share

Dr. Shehla Wynne represents clients in intellectual property matters, with a particular focus on biopharmaceutical patent litigation in district courts and at the Patent Trial and Appeal Board (PTAB). She has experience with issues arising under the Hatch-Waxman Act, the Biologics Price Competition and Innovation Act (BPCIA), and the Defend Trade Secrets Act (DTSA). Her experience spans discovery, motion practice, trial, and appeals. Shehla also has experience in IP due diligence evaluations and competitive landscape analyses in the biotechnology and medical device sectors.

From 2019 to 2020, Shehla served as a law clerk to the Honorable Kathleen M. O'Malley of the United States Court of Appeals for the Federal Circuit. Prior to practicing law, Shehla earned her doctorate in biochemistry and molecular biology at Georgetown University, where her research centered on the molecular mechanisms of prostate cancer cell migration. She has coauthored several peer-reviewed articles in the field of cancer research. While in law school, Shehla was executive production editor from 2013 to 2014 of the AIPLA Quarterly Journal, a publication of the American Intellectual Property Law Association.

Shehla is a co-founder of Desi Writers' Lounge, a nonprofit organization committed to furthering literary awareness in South Asia.

Experience

  • Merck unit resolves DJ action involving pneumococcal vaccine patentsJones Day represented Merck Sharp & Dohme Corp. in an action in Delaware district court against Pfizer (through its subsidiaries including Wyeth, LLC) involving several patents on Wyeth’s vaccine technology.
  • REGENXBIO sues Aldevron for infringement of patented host cells used to make DNA for gene therapy applicationsJones Day represents REGENXBIO Inc. in a patent infringement lawsuit brought against Aldevron LLC claiming that without authorization, Aldevron used and manufactured cultured host cells containing recombinant nucleic acid molecules with sequences encoding AAV8 capsid protein(s) and a heterologous non-AAV sequence.
  • Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Amneal and Kashiv related to OxyContin®Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against MylanJones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue.
  • Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against KVK-Tech and AbhaiJones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Cardinal Health acquires The Harvard Drug Group for $1.115 billionJones Day advised Cardinal Health in its acquisition of The Harvard Drug Group, a distributor of generic pharmaceuticals, over-the-counter medications, and related products to retail, institutional, and alternate care customers from Court Square Capital Partners for $1.115 billion.
  • Purdue Pharma defends against claims of patent infringementJones Day represents Purdue Pharma L.P., The P.F. Laboratories, Inc., and Purdue Pharmaceuticals L.P. in a patent infringement litigation brought by plaintiff Depomed, Inc., based on Purdue's manufacture and sale of its own patented controlled-release OxyContin(R) pain relief medication.
    • View All

    May 2018 Alerts

    Delaware District Dismisses BPCIA "Private Right" Claim; Says Controversy not Sufficiently Immediate

    December 2017 Alerts

    Federal Circuit Rules BPCIA Preempts State Law

    November 2017 Commentaries

    Federal Circuit Clarifies Probative Value of Patent Dance Statements

    May 2017 Jones Day Publications

    Supreme Court Hears Oral Arguments in Sandoz Inc. v. Amgen Inc.

    January 2017 Jones Day Publications

    Key Patent Law Decisions of 2016

    April 2016 Jones Day Publications

    Key Patent Law Decisions of 2015

    June 2015 Commentaries

    2015 Patent Reform: Amendments to H.R. 9 and S. 1137

    May 2015 Commentaries

    2015 Patent Reform: Protecting American Talent and Entrepreneurship Act of 2015 (S. 1137)

    April 2015 Jones Day Publications

    Claim Construction, Findings of Fact, and Indefiniteness in the Wake of Teva v. Sandoz

    March 2015 Commentaries

    Key Patent Law Decisions of 2014
    View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.